




Monday 28 April 2025

### Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Friday 4 April 2025. I am pleased to confirm the following.

### 1.Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)



### 2.Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)

Total number of patients with ICD 61 treated with SACT (This includes all patients on the following: Abiraterone, apalutamide, enzalutamide, Docetaxel Darolutamide, Docetaxel single agent, Cabazitaxel : 2023 = 148, 2024 = 167

- Abiraterone (Zytiga) : 2023 = 7 , 2024 = 5
- Enzalutamide (Xtandi): 2023= 87, 2024 = 92
- Apalutamide (Erleada): 2023=21, 2024=20
- Darolutamide (Nubeqa) with docetaxel: 2023= 11, 2024=21
- Docetaxel : 2023= 16, 2024= 23

# 3.Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)





We are unable to get this detail as many patients are linked with the GP

## 4.Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic)

Docetaxel : 2023= 16, 2024= 23

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.